Effect of daBIGatran and rivaROXaban on Platelets

Effect of daBIGatran and rivaROXaban on Platelets - BIG-ROX-P

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003157

Enrollment

Registered

2011-07-13

Start date

2011-08-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I21.1

Interventions

Group 1: Patients with first detected atrial fibrillation usually have an indication for OAC. After the physicians´ decision for a long-term treatment with dabigatran or rivaroxaban venous blood will

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: first detected AF and OAC with dabigatran or rivaroxaban, informed consent

Exclusion criteria

Exclusion criteria: difficult venous puncture

Design outcomes

Primary

Measure	Time frame
change (?) of platelet aggregation assessed by light transmittance aggregometry (LTA) before and after medication.	—

Secondary

Measure	Time frame
change (?) of platelet function assessed by Multiplate, VerifyNow and platelet biomarkers before and after medication.	—

Countries

Germany

Contacts

Public ContactChristoph Olivier

Universitätsklinikum Freiburg Innere Medizin 3

Christoph.Olivier@Uniklinik-Freiburg.de004976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 10, 2026